Pharmalittle: We’re reading about a Bristol-Pfizer direct-to-consumer sales plan, Sarepta layoffs, and more
Report found business relationships between telehealth and pharma companies may indirectly lead patients toward certain branded drugs
Related Articles
FDA to request Sarepta Therapeutics halt shipments of Duchenne gene therapy
The FDA will request Sarepta Therapeutics stop all shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, following two deaths tied to the product.
We are mothers of Duchenne patients. Recent setbacks with Sarepta must not stop progress
Despite the risks of gene therapy, “we chose the risk of action over reticence,” write two Duchenne mothers.
FDA to request Sarepta Therapeutics halt shipments of Duchenne gene therapy
The FDA will request Sarepta Therapeutics stop all shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, following two deaths tied to the product.
Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
After second Sarepta death, Duchenne muscular dystrophy community is racked by recrimination and worry
Another gene therapy death of a Duchenne patient has some parents and doctors criticizing the FDA’s actions, even as other parents still push for the…
FDA to request Sarepta Therapeutics halt shipments of Duchenne gene therapy
The FDA will request Sarepta Therapeutics stop all shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, following two deaths tied to the product.
FDA to request Sarepta Therapeutics halt shipments of Duchenne gene therapy
The FDA will request Sarepta Therapeutics stop all shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, following two deaths tied to the product.
Why overdose deaths could increase with the GOP tax law
In today’s Morning Rounds newsletter: MAHA takes on Coca-Cola, how Medicaid data will be used to track immigrants, and how overdose deaths could rise with…
GOP tax law will increase overdose deaths by 1,000 each year, analysis finds
Losing access to addiction medications doubles overdose risk. A new analysis says projected Medicaid cuts could add 1,000 opioid deaths yearly.